Answers are grounded in this paper and cite their sources.
Purpose Combination therapies (CTs) and biomarker-guided treatment selection are increasingly central to oncology, yet how closely patients’ perceived understanding matches their actual understanding is unknown. We examined whether patients recognise this gap, how benefit versus harm literacy compares and how far both vary by country. Methods A 29-item anonymous survey in five languages ran for 90 days via Cancer Patients Europe networks. Individual responses were analysed, allowing items to be cross-tabulated within respondents. Proportions carry Wilson 95% CIs; the paired benefit–harm comparison uses McNemar’s test; country differences use χ 2 with Holm adjustment and multivariable logistic regression. Results Of 1446 respondents, 70.4% ( n = 1103) felt adequately informed, yet 45.9% ( n = 985) had never been told about a combination approach and 39.8% ( n = 937) did not know whether biomarker testing guided care; linked within individuals, 25.8% (95% CI 23.2–28.6) both felt adequately informed and had never been told—adequacy misclassifies about one patient in four. Patients were over three times as likely to name a benefit but no harm than the reverse (195 vs. 55 discordant pairs; McNemar P < 0.001). Country differences persisted after adjustment (Italy adjusted OR 2.09, 1.34–3.26; Germany 1.62, 1.07–2.45; reference United Kingdom). Conclusion Patient-reported information adequacy misclassifies about a quarter of patients, communication favours benefits over harms within individuals and country differences survive adjustment—locating the deficit in how systems communicate. Practice should replace satisfaction-based metrics with comprehension checks, adopt toxicity-explicit decision aids, standardise biomarker-result communication and scale advocacy-linked navigation.
No takes yet. Share an insight, caveat, or question.
Fricke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: